SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume... | May 25, 2023
United States Samantha Hilson Sandler Jim Cassidy Fred Hutchinson Cancer Research Center European Organization For Research European Consensus Initiative
Source: marketscreener.com